Skip to main content
. 2016 Feb 23;68(3):299–307. doi: 10.1002/acr.22676

Figure 3.

Figure 3

Mean change from baseline in the modified Sharp/van der Heijde score (SHS) at week 24 by baseline methotrexate (MTX) dose category (intent‐to‐treat population; MTX 2‐dose categorization). Interaction P value between MTX <15 mg/week and MTX ≥15 mg/week across treatment groups based on analysis of covariance (ANCOVA). Individual group P values based on ANCOVA. CZP = certolizumab pegol.